AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20563294 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment targets for LDL-C ≤100 mg/dL and systolic BP ≤130 mmHg
Number of subjects: 0
Study 17069666 — intervention group
Group type: EXPERIMENTAL
Intervention: GHQ-28 Farsi version
Number of subjects: 204
Study 17069666 — intervention group
Group type: EXPERIMENTAL
Intervention: GHQ-15 (derived short form)
Number of subjects: 204
Study 15149896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 57
Study 15149896 — intervention group
Group type: COMPARATOR
Intervention: Supportive Psychotherapy (SUPPORT)
Number of subjects: 57
Study 12102278 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly dose of 100 mg of leflunomide
Number of subjects: 16
Study 12102278 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose of leflunomide
Number of subjects: 16
Study 9695721 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (40 mg total intravenous dose) in addition to baseline dual immunosuppression (cyclosporine and steroids)
Number of subjects: 0
Study 7907646 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-type hypersensitivity (DTH) testing
Number of subjects: 336
Study 7907646 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive patients (response > 2 mm to any antigens)
Number of subjects: 336
Study 2673516 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of semisynthetic human insulin (Novolin) providing a 70:30 ratio of NPH to regular insulin
Number of subjects: 72
Study 2673516 — intervention group
Group type: COMPARATOR
Intervention: Variable ratio of semisynthetic human insulin, regular and NPH (control group)
Number of subjects: 72
Study 2673516 — intervention group
Group type: COMPARATOR
Intervention: Both groups (fixed-ratio and control)
Number of subjects: 72
Study 1151293 — intervention group
Group type: EXPERIMENTAL
Intervention: nurse‐proctocol treatment plan
Number of subjects: 146
Study 1151293 — intervention group
Group type: COMPARATOR
Intervention: physician treatment plan
Number of subjects: 146
Study 31520838 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouse allergen reduction
Number of subjects: 0
Study 30395904 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg once daily during and up to 3 months after RT
Number of subjects: 23
Study 30395904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 28891544 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidrum
Number of subjects: 240
Study 28891544 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi-Jet
Number of subjects: 240
Study 28891544 — intervention group
Group type: COMPARATOR
Intervention: Loss of Resistance (LOR)
Number of subjects: 240
Study 25724455 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab dosing based on therapeutic drug monitoring (TCs)
Number of subjects: 263
Study 25724455 — intervention group
Group type: COMPARATOR
Intervention: Infliximab dosing based on clinical features
Number of subjects: 263
Study 25724455 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose escalation to reach TCs of 3-7 μg/mL
Number of subjects: 263
Study 25724455 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose reduction for TCs >7 μg/mL
Number of subjects: 263
Study 24382088 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity treatment
Number of subjects: 100
Study 24382088 — intervention group
Group type: COMPARATOR
Intervention: Low intensity treatment
Number of subjects: 100
Study 21992849 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose human atrial natriuretic peptide
Number of subjects: 40
Study 21992849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19535720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 230
Study 19535720 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulator guidance
Number of subjects: 230
Study 17470516 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling for 60 min at 65% of maximal heart rate
Number of subjects: 12
Study 17470516 — intervention group
Group type: COMPARATOR
Intervention: Resting (control)
Number of subjects: 12
Study 15894969 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard CR (33 sessions for 3 months)
Number of subjects: 392
Study 15894969 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed CR (33 sessions for 12 months)
Number of subjects: 392
Study 15894969 — intervention group
Group type: COMPARATOR
Intervention: Standard CR
Number of subjects: 392
Study 15894969 — intervention group
Group type: COMPARATOR
Intervention: Distributed CR
Number of subjects: 392
Study 15894969 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard CR and Distributed CR
Number of subjects: 392
Study 12160277 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hodgkin lymphoma (NHL)
Number of subjects: 165
Study 10378911 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial running speed of 3.0 km x h(‐1) below the RS‐LT
Number of subjects: 8
Study 10378911 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial running speed of 0.5 km x h(‐1) below the RS‐LT
Number of subjects: 8
Study 10378911 — intervention group
Group type: EXPERIMENTAL
Intervention: RS‐LT
Number of subjects: 8
Study 7783109 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg once daily)
Number of subjects: 461
Study 7783109 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (10-40 mg once daily)
Number of subjects: 461
Study 7783109 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (continued for 2 years)
Number of subjects: 461
Study 2083405 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen-antibody complexes
Number of subjects: 30
Study 2083405 — intervention group
Group type: COMPARATOR
Intervention: Carrier buffer (control)
Number of subjects: 30
Study 395631 — intervention group
Group type: EXPERIMENTAL
Intervention: jejunoileostomy with a 3:1 jejunoileal ratio
Number of subjects: 95
Study 395631 — intervention group
Group type: EXPERIMENTAL
Intervention: jejunoileostomy with a 1:3 jejunoileal ratio
Number of subjects: 95
Study 395631 — intervention group
Group type: COMPARATOR
Intervention: non‐operative management
Number of subjects: 95
Study 31156168 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies and facilitators
Number of subjects: 17
Study 31156168 — intervention group
Group type: EXPERIMENTAL
Intervention: Embedding research into routine patient care
Number of subjects: 17
Study 31156168 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration with services to identify eligible patients
Number of subjects: 17
Study 31156168 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and engaging trial staff
Number of subjects: 17
Study 31156168 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing clear and concise study information to patients
Number of subjects: 17
Study 27965049 — intervention group
Group type: EXPERIMENTAL
Intervention: Rong‐Yang‐Jyh‐Gan‐Tang (RYJGT) 15g/day for 12 weeks
Number of subjects: 36
Study 27965049 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 36
Study 27965049 — intervention group
Group type: EXPERIMENTAL
Intervention: Rong‐Yang‐Jyh‐Gan‐Tang (RYJGT)
Number of subjects: 36
Study 27965049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 25992812 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 mm shaft diameter esophageal stent
Number of subjects: 100
Study 25992812 — intervention group
Group type: COMPARATOR
Intervention: 23 mm shaft diameter esophageal stent
Number of subjects: 100
Study 25992812 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-diameter stent (18 mm)
Number of subjects: 100
Study 25992812 — intervention group
Group type: COMPARATOR
Intervention: Large-diameter stent (23 mm)
Number of subjects: 100
Study 23869828 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-heated infusion solutions (colloids and crystalloids)
Number of subjects: 29
Study 23869828 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia with actively heated mothers
Number of subjects: 29
Study 23869828 — intervention group
Group type: COMPARATOR
Intervention: Non-heated mothers operated under subarachnoid anaesthesia
Number of subjects: 29
Study 21803933 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS combined with constraint-induced movement therapy (CIMT)
Number of subjects: 14
Study 21803933 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS combined with constraint-induced movement therapy (CIMT)
Number of subjects: 14
Study 19699854 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 530348 2.5 mg daily
Number of subjects: 27000
Study 19699854 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 27000
Study 16394051 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoxynol-9
Number of subjects: 235
Study 15492133 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiorphan (30 nmol/min)
Number of subjects: 10
Study 15492133 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (30 to 300 pmol/min)
Number of subjects: 10
Study 15492133 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (10 to 100 pmol/min)
Number of subjects: 10
Study 15492133 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (2 to 8 mug/min)
Number of subjects: 10
Study 15492133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10516738 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ combination therapy (starting with irbesartan 75 mg/HCTZ 12.5 mg once daily, titrated to irbesartan 150 mg/HCTZ 12.5 mg, then to irbesartan 300 mg/HCTZ 25 mg if necessary)
Number of subjects: 1098
Study 10516738 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ combination therapy
Number of subjects: 1098
Study 7854377 — intervention group
Group type: EXPERIMENTAL
Intervention: D allele of the ACE gene
Number of subjects: 1250
Study 7854377 — intervention group
Group type: COMPARATOR
Intervention: Control group (no D allele)
Number of subjects: 1250
Study 2371577 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-beta-glucosaminidase (NAG) excretion measurement in patients with upper urinary tract infections
Number of subjects: 57
Study 2371577 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-beta-glucosaminidase (NAG) excretion measurement in patients with lower urinary tract infections
Number of subjects: 57
Study 2371577 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-beta-glucosaminidase (NAG) excretion measurement in patients with lower urinary tract symptoms and underlying diseases
Number of subjects: 57
Study 2371577 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 57
Study 2371577 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lower urinary tract infections
Number of subjects: 57
Study 7247360 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim (TMP) 200 mg twice daily
Number of subjects: 48
Study 7247360 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole-trimethoprim (SMX-TMP) 800/160 mg twice daily
Number of subjects: 48
Study 7247360 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 48
Study 31615781 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine ultrasonography in the third trimester (two routine biometry scans at 28‐30 and 34‐36 weeks' gestation)
Number of subjects: 13046
Study 31615781 — intervention group
Group type: COMPARATOR
Intervention: Usual care (serial fundal height measurements with clinically indicated ultrasonography)
Number of subjects: 13046
Study 28744102 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic alendronate sodium tablets (70 mg)
Number of subjects: 36
Study 28744102 — intervention group
Group type: COMPARATOR
Intervention: Fosamax® tablets (70 mg) - first dose
Number of subjects: 36
Study 28744102 — intervention group
Group type: COMPARATOR
Intervention: Fosamax® tablets (70 mg) - second dose
Number of subjects: 36
Study 25083010 — intervention group
Group type: EXPERIMENTAL
Intervention: Professionally administered CBT‐I (PCBT‐I; n = 81)
Number of subjects: 242
Study 25083010 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based CBT‐I (VCBT‐I; n = 80)
Number of subjects: 242
Study 25083010 — intervention group
Group type: COMPARATOR
Intervention: No treatment (CTL; n = 81)
Number of subjects: 242
Study 22409766 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT) program for 5 weeks
Number of subjects: 0
Study 20840188 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent condition (voucher-based CM)
Number of subjects: 166
Study 20840188 — intervention group
Group type: COMPARATOR
Intervention: Non-contingent condition
Number of subjects: 166
Study 17356993 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone with 20 minutes counseling and weekly visits
Number of subjects: 142
Study 17356993 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine/naloxone with 45 minutes counseling and thrice weekly visits
Number of subjects: 142
Study 17356993 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall satisfaction score
Number of subjects: 142
Study 17356993 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication and ancillary services
Number of subjects: 142
Study 17356993 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactions with other opioid-dependent patients and referrals to Narcotics Anonymous
Number of subjects: 142
Study 17356993 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender and non-White ethnicity/race
Number of subjects: 142
Study 15732027 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemic patients in the IN‐CHF Registry
Number of subjects: 7411
Study 15732027 — intervention group
Group type: COMPARATOR
Intervention: Patients without anemia in the IN‐CHF Registry
Number of subjects: 7411
Study 15732027 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemic patients in the Val‐HeFT trial
Number of subjects: 7411
Study 15732027 — intervention group
Group type: COMPARATOR
Intervention: Patients without anemia in the Val‐HeFT trial
Number of subjects: 7411
Study 12352161 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced magnetic resonance angiography (CE-MRA)
Number of subjects: 43
Study 12352161 — intervention group
Group type: COMPARATOR
Intervention: Digital subtraction angiography (x-ray DSA)
Number of subjects: 43
Study 10429837 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir 10 mg from the Diskhaler
Number of subjects: 13
Study 10429837 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir 10 mg from the prototype device
Number of subjects: 13
Study 10429837 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall inhalation of zanamivir
Number of subjects: 13
Study 7591715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous betahistine (57, 114, and 285 micrograms i.d.)
Number of subjects: 11
Study 7591715 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral betahistine plus cetirizine and cimetidine
Number of subjects: 11
Study 7591715 — intervention group
Group type: COMPARATOR
Intervention: Histamine (1 microgram i.d.)
Number of subjects: 11
Study 7591715 — intervention group
Group type: COMPARATOR
Intervention: Oral betahistine alone
Number of subjects: 11
Study 2124446 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drug for a mean period of 6 weeks (range: 3‐12 weeks)
Number of subjects: 102
Study 2124446 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (n = 61) with a percentage of pathological DBP readings greater than 90 mmHg during daytime as high as 50% or more
Number of subjects: 102
Study 2124446 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (n = 41) with a percentage of pathological DBP readings less than 50%
Number of subjects: 102
Study 7447225 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study 7447225 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 0
Study 7447225 — intervention group
Group type: COMPARATOR
Intervention: Cholesterol-lowering diet
Number of subjects: 0
Study 30548458 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentee-reported relationship quality
Number of subjects: 1360
Study 30548458 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentor-reported use of goal-setting and feedback-oriented activities
Number of subjects: 1360
Study 30548458 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between relationship quality and goal-setting/feedback activities
Number of subjects: 1360
Study 29173856 — intervention group
Group type: EXPERIMENTAL
Intervention: Essix retainers
Number of subjects: 176
Study 29173856 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrap-around retainers
Number of subjects: 176
Study 29173856 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fixed retainers and Essix
Number of subjects: 176
Study 29173856 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal occlusion)
Number of subjects: 176
Study 27392196 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week family-based healthy lifestyle intervention
Number of subjects: 70
Study 23990233 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (2 mg + 2 mg) administered during PCI
Number of subjects: 32
Study 23990233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 22250038 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (24 µg)
Number of subjects: 8
Study 22250038 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (18 µg)
Number of subjects: 8
Study 19583040 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisolv chemo‐mechanical technique and Duraphat (2.23% F) fluoride varnish
Number of subjects: 40
Study 19583040 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat alone
Number of subjects: 40
Study 19583040 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous fluoride solution (8%)
Number of subjects: 40
Study 19583040 — intervention group
Group type: COMPARATOR
Intervention: All groups (Carisolv/Duraphat, Duraphat, Stannous fluoride)
Number of subjects: 40
Study 17325272 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein (LDL) levels above individual preadmission LDL goals as defined by NCEP-ATPIII guidelines
Number of subjects: 1040
Study 17325272 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously diagnosed dyslipidemia
Number of subjects: 1040
Study 17325272 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering agents (LLA)
Number of subjects: 1040
Study 17325272 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering agents (LLA) indicated
Number of subjects: 1040
Study 17325272 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower LDL therapeutic targets
Number of subjects: 1040
Study 17325272 — intervention group
Group type: EXPERIMENTAL
Intervention: Preadmission LLA
Number of subjects: 1040
Study 17325272 — intervention group
Group type: EXPERIMENTAL
Intervention: Calendar time
Number of subjects: 1040
Study 16960636 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared therapy (IR therapy)
Number of subjects: 40
Study 16960636 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 40
Study 14691360 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive‐behavioral family‐based therapy (CBFT)
Number of subjects: 77
Study 14691360 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive‐behavioral family‐based therapy (CBFT)
Number of subjects: 77
Study 14691360 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 77
Study 11054434 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal function-based dosing
Number of subjects: 38
Study 11054434 — intervention group
Group type: COMPARATOR
Intervention: Surface area-based dosing
Number of subjects: 38
Study 11054434 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC
Number of subjects: 38
Study 8972014 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel at doses of 10, 25, 50, 75 or 100 mg OD
Number of subjects: 150
Study 8972014 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine 250 mg BID
Number of subjects: 150
Study 1738517 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel pessary containing 10 mg of prostaglandin E2
Number of subjects: 215
Study 6824553 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin 30 mg at night
Number of subjects: 58
Study 6824553 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 58
Study 31553945 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking School Bus (WSB) program
Number of subjects: 45
Study 29048206 — intervention group
Group type: COMPARATOR
Intervention: 3500 Shock Waves Per Session (SWPS) in Group A
Number of subjects: 307
Study 29048206 — intervention group
Group type: EXPERIMENTAL
Intervention: 7000 Shock Waves Per Session (SWPS) in Group B
Number of subjects: 307
Study 28929669 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Chaiping decoction (6 doses per week, one dose every day in two times by oral administration)
Number of subjects: 119
Study 28929669 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Chaiping decoction
Number of subjects: 119
Study 25081808 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily weight tracking for 6 months
Number of subjects: 30
Study 25081808 — intervention group
Group type: COMPARATOR
Intervention: Weekly weight tracking for 6 months
Number of subjects: 30
Study 25081808 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily weight tracking
Number of subjects: 30
Study 25081808 — intervention group
Group type: COMPARATOR
Intervention: Weekly weight tracking
Number of subjects: 30
Study 22539020 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (15 mg daily for 12 weeks)
Number of subjects: 44
Study 22539020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 19411519 — intervention group
Group type: EXPERIMENTAL
Intervention: Etched only the enamel (group A)
Number of subjects: 100
Study 19411519 — intervention group
Group type: EXPERIMENTAL
Intervention: Etched both enamel and dentin (group B)
Number of subjects: 100
Study 19411519 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall retention rate
Number of subjects: 100
Study 19411519 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 100
Study 17207911 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GP)
Number of subjects: 110